<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01398943</url>
  </required_header>
  <id_info>
    <org_study_id>AHA00115CS</org_study_id>
    <nct_id>NCT01398943</nct_id>
  </id_info>
  <brief_title>Nitric Oxide Bioavailability in Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>Regulation of Nitric Oxide Bioavailability in Chronic Obstructive Pulmonary Disease: A Mechanistic Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Augusta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Augusta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      More patients with chronic obstructive pulmonary disease (COPD) die from cardiovascular
      disease than direct pulmonary complications. Inflammation and oxidative stress,
      characteristic in COPD, are likely contributors to the reduction in nitric oxide (NO)
      bioavailability and vascular endothelial dysfunction in COPD patients; however, this has yet
      to be determined. Thus, the overall objective of this proposal is to identify the role of NO
      bioavailability in contributing to vascular endothelial dysfunction in patients with COPD and
      to provide insight into the molecular mechanisms involved. Our central hypothesis is that
      inflammation and oxidative stress, both independently, contribute to the reduction in NO
      bioavailability and vascular endothelial dysfunction in patients with COPD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Flow-Mediated Dilation (FMD) - Subjects will lie in the supine position for 20 minutes to
      obtain hemodynamic steady state. A blood pressure cuff (Hokanson) will be placed around the
      forearm (distal to the Doppler transducer) and rapidly inflated to 250 mmHg for 5 minutes
      (circulatory arrest). Simultaneous ultrasound images of the vessel (B-mode) and Doppler
      waveforms will be collected 10 seconds prior to and for 2 minutes following deflation of the
      cuff. All B-mode images will be analyzed using automated edge detection software (Medical
      Imaging Applications), while intensity weighted velocity spectra segments will be saved to
      the GE Logiq 7 hard drive for off-line blood velocity waveform analysis. P.I. has utilized
      the traditional method of brachial artery flow-mediated dilation (FMD) induced by reactive
      hyperemia to assess vascular endothelial function in populations ranging from young healthy
      adults to older adults with pathological conditions.

      Spygmocor - Pulse Wave Velocity (PWV) - A Spygmocor® device will be used at baseline and
      following each protocol to assess PWV. PWV analysis provides a non-invasive assessment of
      arterial stiffness. Increased arterial stiffness is known to be associated with
      cardiovascular disease. The participant is required to lie in a resting position for
      approximately 30-45 minutes. The research assistant will place ECG electrode sensors at the
      carotid, femoral, radial and distal artery locations. A highly sensitive pen-like device,
      called a tonometer, is then gently applied to record the velocity of the blood flow between
      each of the points.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Flow-Mediated Dilation (FMD)</measure>
    <time_frame>Post FMD was taken approximately 110 min after baseline</time_frame>
    <description>Brachial artery FMD induced by reactive hyperemia will be used to assess vascular endothelial function at baseline and several hours after each experimental intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulse Wave Velocity</measure>
    <time_frame>Post PWV was taken approximately 90 min after baseline</time_frame>
    <description>A measure of vascular stiffness at baseline and several hours after each experimental intervention.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>COPD Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with COPD
AOC protocol: Brachial artery flow-mediated dilation, direct assessment of oxidative stress via EPR spectroscopy (O2-) and biomarkers of oxidative stress (8-isoprostane, LH, SOD) will be assessed at baseline and 2 hours following ingestion of a single oral antioxidant cocktail (1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid.) Antioxidant Cocktail: 1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid
BH4 protocol: Brachial artery flow-mediated dilation (FMD), markers of inflammation, and markers of oxidative stress will be assessed at baseline and following an increase in nitric oxide bioavailability after administering a single dose = 5 mg/kg of Tetrahydrobiopterin (BH4)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy age- and sex- matched controls
AOC protocol: Brachial artery flow-mediated dilation, direct assessment of oxidative stress via EPR spectroscopy (O2-) and biomarkers of oxidative stress (8-isoprostane, LH, SOD) will be assessed at baseline and 2 hours following ingestion of a single oral antioxidant cocktail (1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid.) Antioxidant Cocktail: 1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid
BH4 protocol: Brachial artery flow-mediated dilation (FMD), markers of inflammation, and markers of oxidative stress will be assessed at baseline and following an increase in nitric oxide bioavailability after administering a single dose = 5 mg/kg of Tetrahydrobiopterin (BH4)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tetrahydrobiopterin (BH4)</intervention_name>
    <description>single dose = 5 mg/kg</description>
    <arm_group_label>COPD Patients</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
    <other_name>Kuvan (Sapropterin Dihydrochloride)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Antioxidant Cocktail</intervention_name>
    <description>1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid</description>
    <arm_group_label>COPD Patients</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with COPD (GOLD stages II-IV) and matched healthy controls

          -  Caucasian or African American

          -  Both men and women

          -  Current and former smokers

        Exclusion Criteria:

          -  GOLD Stage I

          -  Clinical diagnosis of heart disease, hypertension, or metabolic disease

          -  Vasoactive medications (i.e. nitrates, beta-blockers, ACE inhibitors, Viagra, etc.)

          -  Pulmonary hypertension

          -  Hypothyroidism

          -  Hyper-homocysteinemia

          -  Interstitial lung disease

          -  Phenylketonuria

          -  Pregnancy

          -  Sleep apnea

          -  Anemia

          -  Raynod's phenomenon

          -  Gangrene of the digits

          -  History of low platelets or coagulopathies

          -  Aspirin sensitivity or allergy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ryan A Harris, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Augusta University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Selvaraj CL, Gurm HS, Gupta R, Ellis SG, Bhatt DL. Chronic obstructive pulmonary disease as a predictor of mortality in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2005 Sep 15;96(6):756-9.</citation>
    <PMID>16169353</PMID>
  </reference>
  <reference>
    <citation>Anthonisen NR, Connett JE, Enright PL, Manfreda J; Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med. 2002 Aug 1;166(3):333-9.</citation>
    <PMID>12153966</PMID>
  </reference>
  <reference>
    <citation>Schächinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000 Apr 25;101(16):1899-906.</citation>
    <PMID>10779454</PMID>
  </reference>
  <reference>
    <citation>Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000 Mar 7;101(9):948-54.</citation>
    <PMID>10704159</PMID>
  </reference>
  <reference>
    <citation>Wheatcroft SB, Williams IL, Shah AM, Kearney MT. Pathophysiological implications of insulin resistance on vascular endothelial function. Diabet Med. 2003 Apr;20(4):255-68. Review.</citation>
    <PMID>12675638</PMID>
  </reference>
  <reference>
    <citation>Knowles RG, Moncada S. Nitric oxide synthases in mammals. Biochem J. 1994 Mar 1;298 ( Pt 2):249-58. Review.</citation>
    <PMID>7510950</PMID>
  </reference>
  <reference>
    <citation>Green D. Point: Flow-mediated dilation does reflect nitric oxide-mediated endothelial function. J Appl Physiol (1985). 2005 Sep;99(3):1233-4; discussion 1237-8.</citation>
    <PMID>16103524</PMID>
  </reference>
  <reference>
    <citation>Uehata A, Lieberman EH, Gerhard MD, Anderson TJ, Ganz P, Polak JF, Creager MA, Yeung AC. Noninvasive assessment of endothelium-dependent flow-mediated dilation of the brachial artery. Vasc Med. 1997;2(2):87-92.</citation>
    <PMID>9546961</PMID>
  </reference>
  <reference>
    <citation>Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992 Nov 7;340(8828):1111-5.</citation>
    <PMID>1359209</PMID>
  </reference>
  <reference>
    <citation>Verma S, Buchanan MR, Anderson TJ. Endothelial function testing as a biomarker of vascular disease. Circulation. 2003 Oct 28;108(17):2054-9. Review.</citation>
    <PMID>14581384</PMID>
  </reference>
  <reference>
    <citation>Maiorana A, O'Driscoll G, Taylor R, Green D. Exercise and the nitric oxide vasodilator system. Sports Med. 2003;33(14):1013-35. Review.</citation>
    <PMID>14599231</PMID>
  </reference>
  <reference>
    <citation>Edwards DG, Schofield RS, Lennon SL, Pierce GL, Nichols WW, Braith RW. Effect of exercise training on endothelial function in men with coronary artery disease. Am J Cardiol. 2004 Mar 1;93(5):617-20.</citation>
    <PMID>14996592</PMID>
  </reference>
  <reference>
    <citation>Guerci B, Kearney-Schwartz A, Böhme P, Zannad F, Drouin P. Endothelial dysfunction and type 2 diabetes. Part 1: physiology and methods for exploring the endothelial function. Diabetes Metab. 2001 Sep;27(4 Pt 1):425-34. Review.</citation>
    <PMID>11547216</PMID>
  </reference>
  <reference>
    <citation>Zarubina EG, Mishina EA, Osadchuk MA. [The role of endothelial dysfunction in the pathogenesis of combined cardiopulmonary diseases]. Klin Med (Mosk). 2006;84(5):31-4. Russian.</citation>
    <PMID>16827275</PMID>
  </reference>
  <reference>
    <citation>Barr RG, Mesia-Vela S, Austin JH, Basner RC, Keller BM, Reeves AP, Shimbo D, Stevenson L. Impaired flow-mediated dilation is associated with low pulmonary function and emphysema in ex-smokers: the Emphysema and Cancer Action Project (EMCAP) Study. Am J Respir Crit Care Med. 2007 Dec 15;176(12):1200-7. Epub 2007 Aug 29.</citation>
    <PMID>17761614</PMID>
  </reference>
  <reference>
    <citation>Moro L, Pedone C, Scarlata S, Malafarina V, Fimognari F, Antonelli-Incalzi R. Endothelial dysfunction in chronic obstructive pulmonary disease. Angiology. 2008 Jun-Jul;59(3):357-64. doi: 10.1177/0003319707306141. Epub 2008 Apr 2.</citation>
    <PMID>18388072</PMID>
  </reference>
  <reference>
    <citation>Eickhoff P, Valipour A, Kiss D, Schreder M, Cekici L, Geyer K, Kohansal R, Burghuber OC. Determinants of systemic vascular function in patients with stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008 Dec 15;178(12):1211-8. doi: 10.1164/rccm.200709-1412OC. Epub 2008 Oct 3.</citation>
    <PMID>18836149</PMID>
  </reference>
  <reference>
    <citation>Fukai T. Endothelial GTPCH in eNOS uncoupling and atherosclerosis. Arterioscler Thromb Vasc Biol. 2007 Jul;27(7):1493-5.</citation>
    <PMID>17581829</PMID>
  </reference>
  <reference>
    <citation>Channon KM. Tetrahydrobiopterin: regulator of endothelial nitric oxide synthase in vascular disease. Trends Cardiovasc Med. 2004 Nov;14(8):323-7. Review.</citation>
    <PMID>15596110</PMID>
  </reference>
  <reference>
    <citation>Heitzer T, Brockhoff C, Mayer B, Warnholtz A, Mollnau H, Henne S, Meinertz T, Münzel T. Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers : evidence for a dysfunctional nitric oxide synthase. Circ Res. 2000 Feb 4;86(2):E36-41.</citation>
    <PMID>10666424</PMID>
  </reference>
  <reference>
    <citation>Nandi M, Miller A, Stidwill R, Jacques TS, Lam AA, Haworth S, Heales S, Vallance P. Pulmonary hypertension in a GTP-cyclohydrolase 1-deficient mouse. Circulation. 2005 Apr 26;111(16):2086-90. Epub 2005 Apr 11.</citation>
    <PMID>15824199</PMID>
  </reference>
  <reference>
    <citation>Khoo JP, Zhao L, Alp NJ, Bendall JK, Nicoli T, Rockett K, Wilkins MR, Channon KM. Pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension. Circulation. 2005 Apr 26;111(16):2126-33. Epub 2005 Apr 11.</citation>
    <PMID>15824200</PMID>
  </reference>
  <reference>
    <citation>Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997 Apr 10;336(15):1066-71. Review.</citation>
    <PMID>9091804</PMID>
  </reference>
  <reference>
    <citation>De Boer WI. Cytokines and therapy in COPD: a promising combination? Chest. 2002 May;121(5 Suppl):209S-218S. Review.</citation>
    <PMID>12010854</PMID>
  </reference>
  <reference>
    <citation>Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med. 1996 Feb;153(2):530-4.</citation>
    <PMID>8564092</PMID>
  </reference>
  <reference>
    <citation>Shapiro SD, Senior RM. Matrix metalloproteinases. Matrix degradation and more. Am J Respir Cell Mol Biol. 1999 Jun;20(6):1100-2. Review.</citation>
    <PMID>10340927</PMID>
  </reference>
  <reference>
    <citation>Read MA, Whitley MZ, Williams AJ, Collins T. NF-kappa B and I kappa B alpha: an inducible regulatory system in endothelial activation. J Exp Med. 1994 Feb 1;179(2):503-12.</citation>
    <PMID>7507507</PMID>
  </reference>
  <reference>
    <citation>Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature. 1998 Nov 5;396(6706):77-80.</citation>
    <PMID>9817203</PMID>
  </reference>
  <reference>
    <citation>Atkinson MH, Ménard HA, Kalish GH. Assessment of salsalate, a nonacetylated salicylate, in the treatment of patients with arthritis. Clin Ther. 1995 Sep-Oct;17(5):827-37.</citation>
    <PMID>8595635</PMID>
  </reference>
  <reference>
    <citation>Bombardier C, Peloso PM, Goldsmith CH. Salsalate, a nonacetylated salicylate, is as efficacious as diclofenac in patients with rheumatoid arthritis. Salsalate-Diclofenac Study Group. J Rheumatol. 1995 Apr;22(4):617-24.</citation>
    <PMID>7791151</PMID>
  </reference>
  <reference>
    <citation>Pierce GL, Lesniewski LA, Lawson BR, Beske SD, Seals DR. Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans. Circulation. 2009 Mar 10;119(9):1284-92. doi: 10.1161/CIRCULATIONAHA.108.804294. Epub 2009 Feb 23.</citation>
    <PMID>19237660</PMID>
  </reference>
  <reference>
    <citation>Halliwell B. Free radicals and antioxidants: a personal view. Nutr Rev. 1994 Aug;52(8 Pt 1):253-65. Review.</citation>
    <PMID>7970288</PMID>
  </reference>
  <reference>
    <citation>Celermajer DS, Adams MR, Clarkson P, Robinson J, McCredie R, Donald A, Deanfield JE. Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. N Engl J Med. 1996 Jan 18;334(3):150-4.</citation>
    <PMID>8531969</PMID>
  </reference>
  <reference>
    <citation>Celermajer DS, Sorensen KE, Georgakopoulos D, Bull C, Thomas O, Robinson J, Deanfield JE. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation. 1993 Nov;88(5 Pt 1):2149-55.</citation>
    <PMID>8222109</PMID>
  </reference>
  <reference>
    <citation>Raitakari OT, Adams MR, McCredie RJ, Griffiths KA, Celermajer DS. Arterial endothelial dysfunction related to passive smoking is potentially reversible in healthy young adults. Ann Intern Med. 1999 Apr 6;130(7):578-81.</citation>
    <PMID>10189327</PMID>
  </reference>
  <reference>
    <citation>Macnee W. Pathogenesis of chronic obstructive pulmonary disease. Clin Chest Med. 2007 Sep;28(3):479-513, v. Review.</citation>
    <PMID>17720039</PMID>
  </reference>
  <reference>
    <citation>Rubanyi GM, Vanhoutte PM. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am J Physiol. 1986 May;250(5 Pt 2):H822-7.</citation>
    <PMID>3010744</PMID>
  </reference>
  <reference>
    <citation>Neunteufl T, Kostner K, Katzenschlager R, Zehetgruber M, Maurer G, Weidinger F. Additional benefit of vitamin E supplementation to simvastatin therapy on vasoreactivity of the brachial artery of hypercholesterolemic men. J Am Coll Cardiol. 1998 Sep;32(3):711-6.</citation>
    <PMID>9741516</PMID>
  </reference>
  <reference>
    <citation>Plantinga Y, Ghiadoni L, Magagna A, Giannarelli C, Franzoni F, Taddei S, Salvetti A. Supplementation with vitamins C and E improves arterial stiffness and endothelial function in essential hypertensive patients. Am J Hypertens. 2007 Apr;20(4):392-7.</citation>
    <PMID>17386345</PMID>
  </reference>
  <reference>
    <citation>Title LM, Cummings PM, Giddens K, Genest JJ Jr, Nassar BA. Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease. J Am Coll Cardiol. 2000 Sep;36(3):758-65.</citation>
    <PMID>10987596</PMID>
  </reference>
  <reference>
    <citation>Williams TJ, Howard M, Roget J, Esmore DS. Exercise capacity after combined heart-lung transplantation. Transplant Proc. 1992 Oct;24(5):2018.</citation>
    <PMID>1412956</PMID>
  </reference>
  <reference>
    <citation>Richardson RS, Secher NH, Tschakovsky ME, Proctor DN, Wray DW. Metabolic and vascular limb differences affected by exercise, gender, age, and disease. Med Sci Sports Exerc. 2006 Oct;38(10):1792-6.</citation>
    <PMID>17019301</PMID>
  </reference>
  <reference>
    <citation>Eskurza I, Myerburgh LA, Kahn ZD, Seals DR. Tetrahydrobiopterin augments endothelium-dependent dilatation in sedentary but not in habitually exercising older adults. J Physiol. 2005 Nov 1;568(Pt 3):1057-65. Epub 2005 Sep 1.</citation>
    <PMID>16141271</PMID>
  </reference>
  <reference>
    <citation>Ueda S, Matsuoka H, Miyazaki H, Usui M, Okuda S, Imaizumi T. Tetrahydrobiopterin restores endothelial function in long-term smokers. J Am Coll Cardiol. 2000 Jan;35(1):71-5.</citation>
    <PMID>10636262</PMID>
  </reference>
  <reference>
    <citation>Padilla J, Harris RA, Fly AD, Rink LD, Wallace JP. A comparison between active- and reactive-hyperaemia-induced brachial artery vasodilation. Clin Sci (Lond). 2006 Mar;110(3):387-92.</citation>
    <PMID>16356163</PMID>
  </reference>
  <reference>
    <citation>Plotnick GD, Corretti MC, Vogel RA. Effect of antioxidant vitamins on the transient impairment of endothelium-dependent brachial artery vasoactivity following a single high-fat meal. JAMA. 1997 Nov 26;278(20):1682-6.</citation>
    <PMID>9388088</PMID>
  </reference>
  <reference>
    <citation>Padilla J, Harris RA, Fly AD, Rink LD, Wallace JP. The effect of acute exercise on endothelial function following a high-fat meal. Eur J Appl Physiol. 2006 Oct;98(3):256-62. Epub 2006 Aug 3.</citation>
    <PMID>16896723</PMID>
  </reference>
  <reference>
    <citation>Tsai WC, Li YH, Lin CC, Chao TH, Chen JH. Effects of oxidative stress on endothelial function after a high-fat meal. Clin Sci (Lond). 2004 Mar;106(3):315-9.</citation>
    <PMID>14561213</PMID>
  </reference>
  <reference>
    <citation>Mullen MJ, Kharbanda RK, Cross J, Donald AE, Taylor M, Vallance P, Deanfield JE, MacAllister RJ. Heterogenous nature of flow-mediated dilatation in human conduit arteries in vivo: relevance to endothelial dysfunction in hypercholesterolemia. Circ Res. 2001 Feb 2;88(2):145-51.</citation>
    <PMID>11157665</PMID>
  </reference>
  <reference>
    <citation>Kingwell BA, Formosa M, Muhlmann M, Bradley SJ, McConell GK. Nitric oxide synthase inhibition reduces glucose uptake during exercise in individuals with type 2 diabetes more than in control subjects. Diabetes. 2002 Aug;51(8):2572-80.</citation>
    <PMID>12145173</PMID>
  </reference>
  <reference>
    <citation>Lieberman EH, Gerhard MD, Uehata A, Selwyn AP, Ganz P, Yeung AC, Creager MA. Flow-induced vasodilation of the human brachial artery is impaired in patients &lt;40 years of age with coronary artery disease. Am J Cardiol. 1996 Dec 1;78(11):1210-4.</citation>
    <PMID>8960576</PMID>
  </reference>
  <reference>
    <citation>Harris RA, Nishiyama SK, Wray DW, Tedjasaputra V, Bailey DM, Richardson RS. The effect of oral antioxidants on brachial artery flow-mediated dilation following 5 and 10 min of ischemia. Eur J Appl Physiol. 2009 Nov;107(4):445-53. doi: 10.1007/s00421-009-1147-x. Epub 2009 Aug 11.</citation>
    <PMID>19669786</PMID>
  </reference>
  <reference>
    <citation>Bleeker MW, Kooijman M, Rongen GA, Hopman MT, Smits P. Preserved contribution of nitric oxide to baseline vascular tone in deconditioned human skeletal muscle. J Physiol. 2005 Jun 1;565(Pt 2):685-94. Epub 2005 Mar 31.</citation>
    <PMID>15802292</PMID>
  </reference>
  <reference>
    <citation>Mercier JG, Hokanson JF, Brooks GA. Effects of cyclosporine A on skeletal muscle mitochondrial respiration and endurance time in rats. Am J Respir Crit Care Med. 1995 May;151(5):1532-6.</citation>
    <PMID>7735611</PMID>
  </reference>
  <reference>
    <citation>Casaburi R. Skeletal muscle function in COPD. Chest. 2000 May;117(5 Suppl 1):267S-71S. Review.</citation>
    <PMID>10843945</PMID>
  </reference>
  <reference>
    <citation>Harris RA, Padilla J, Rink LD, Wallace JP. Variability of flow-mediated dilation measurements with repetitive reactive hyperemia. Vasc Med. 2006 Feb;11(1):1-6.</citation>
    <PMID>16669406</PMID>
  </reference>
  <reference>
    <citation>Harris RA, Padilla J, Hanlon KP, Rink LD, Wallace JP. Reproducibility of the flow-mediated dilation response to acute exercise in overweight men. Ultrasound Med Biol. 2007 Oct;33(10):1579-85. Epub 2007 Jun 27.</citation>
    <PMID>17590500</PMID>
  </reference>
  <reference>
    <citation>Vogel RA, Corretti MC, Plotnick GD. Effect of a single high-fat meal on endothelial function in healthy subjects. Am J Cardiol. 1997 Feb 1;79(3):350-4.</citation>
    <PMID>9036757</PMID>
  </reference>
  <reference>
    <citation>Sander M, Chavoshan B, Victor RG. A large blood pressure-raising effect of nitric oxide synthase inhibition in humans. Hypertension. 1999 Apr;33(4):937-42.</citation>
    <PMID>10205227</PMID>
  </reference>
  <reference>
    <citation>Goldfine AB, Silver R, Aldhahi W, Cai D, Tatro E, Lee J, Shoelson SE. Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin Transl Sci. 2008 May;1(1):36-43. doi: 10.1111/j.1752-8062.2008.00026.x.</citation>
    <PMID>19337387</PMID>
  </reference>
  <reference>
    <citation>Bailey DM, Davies B, Young IS, Jackson MJ, Davison GW, Isaacson R, Richardson RS. EPR spectroscopic detection of free radical outflow from an isolated muscle bed in exercising humans. J Appl Physiol (1985). 2003 May;94(5):1714-8. Epub 2003 Mar 7.</citation>
    <PMID>12626489</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2011</study_first_submitted>
  <study_first_submitted_qc>July 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2011</study_first_posted>
  <results_first_submitted>November 17, 2016</results_first_submitted>
  <results_first_submitted_qc>June 27, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 25, 2017</results_first_posted>
  <last_update_submitted>November 9, 2017</last_update_submitted>
  <last_update_submitted_qc>November 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Augusta University</investigator_affiliation>
    <investigator_full_name>Ryan Harris</investigator_full_name>
    <investigator_title>Assistant Professor, Director Laboratory of Integrative Vascular and Exercise Physiology</investigator_title>
  </responsible_party>
  <keyword>flow-mediated dilation</keyword>
  <keyword>arterial stiffness</keyword>
  <keyword>intima-media thickness</keyword>
  <keyword>pulse wave velocity</keyword>
  <keyword>dual energy x-ray absorptiometry</keyword>
  <keyword>inflammatory markers</keyword>
  <keyword>blood lipids</keyword>
  <keyword>tetrahydrobiopterin</keyword>
  <keyword>body mass index</keyword>
  <keyword>hemoglobin A1c</keyword>
  <keyword>complete blood count</keyword>
  <keyword>oxidative stress biomarkers</keyword>
  <keyword>pulmonary function test</keyword>
  <keyword>lung</keyword>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Thioctic Acid</mesh_term>
    <mesh_term>Nitric Oxide</mesh_term>
    <mesh_term>Antioxidants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>COPD: AOC First, Then Placebo</title>
          <description>Patients with COPD
Brachial artery flow-mediated dilation, direct assessment of oxidative stress via EPR spectroscopy (O2-) and biomarkers of oxidative stress (8-isoprostane, LH, SOD) were assessed at baseline and 2 hours following ingestion of an oral antioxidant cocktail (1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid.) Antioxidant Cocktail: 1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid.
After a minimum of 2 days washout, patients returned to perform all measures again but were given microcrystalline cellulose capsules as a placebo.</description>
        </group>
        <group group_id="P2">
          <title>COPD: Placebo First, Then AOC</title>
          <description>Patients with COPD
Brachial artery flow-mediated dilation, direct assessment of oxidative stress via EPR spectroscopy (O2-) and biomarkers of oxidative stress (8-isoprostane, LH, SOD) was assessed at baseline and 2 hours following ingestion of microcrystalline cellulose capsules as a placebo.
After a minimum of 2 days washout, patients returned to perform all measures again but were given an oral antioxidant cocktail (1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid.) Antioxidant Cocktail: 1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid.</description>
        </group>
        <group group_id="P3">
          <title>Controls: AOC First, Then Placebo</title>
          <description>Healthy age- and sex- matched controls
Brachial artery flow-mediated dilation, direct assessment of oxidative stress via EPR spectroscopy (O2-) and biomarkers of oxidative stress (8-isoprostane, LH, SOD) were assessed at baseline and 2 hours following ingestion of an oral antioxidant cocktail (1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid.) Antioxidant Cocktail: 1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid.
After a minimum of 2 days washout, subjects returned to perform all measures again but were given microcrystalline cellulose capsules as a placebo.</description>
        </group>
        <group group_id="P4">
          <title>Controls: Placebo First, Then AOC</title>
          <description>Brachial artery flow-mediated dilation, direct assessment of oxidative stress via EPR spectroscopy (O2-) and biomarkers of oxidative stress (8-isoprostane, LH, SOD) was assessed at baseline and 2 hours following ingestion of microcrystalline cellulose capsules as a placebo.
After a minimum of 2 days washout, subjects returned to perform all measures again but were given an oral antioxidant cocktail (1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid.) Antioxidant Cocktail: 1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (2-7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All COPD Patients</title>
          <description>Patients with COPD</description>
        </group>
        <group group_id="B2">
          <title>All Controls</title>
          <description>Healthy age- and sex- matched controls</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" spread="2"/>
                    <measurement group_id="B2" value="66" spread="2"/>
                    <measurement group_id="B3" value="66" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="169" spread="2"/>
                    <measurement group_id="B2" value="166" spread="2"/>
                    <measurement group_id="B3" value="168" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Flow-Mediated Dilation (FMD)</title>
        <description>Brachial artery FMD induced by reactive hyperemia will be used to assess vascular endothelial function at baseline and several hours after each experimental intervention.</description>
        <time_frame>Post FMD was taken approximately 110 min after baseline</time_frame>
        <population>Participants included patients diagnosed with COPD and healthy age-matched controls.</population>
        <group_list>
          <group group_id="O1">
            <title>All COPD Patients</title>
            <description>Patients with COPD</description>
          </group>
          <group group_id="O2">
            <title>All Controls</title>
            <description>Healthy age- and sex- matched controls</description>
          </group>
        </group_list>
        <measure>
          <title>Flow-Mediated Dilation (FMD)</title>
          <description>Brachial artery FMD induced by reactive hyperemia will be used to assess vascular endothelial function at baseline and several hours after each experimental intervention.</description>
          <population>Participants included patients diagnosed with COPD and healthy age-matched controls.</population>
          <units>percentage of change in FMD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="0.5"/>
                    <measurement group_id="O2" value="6.7" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AOC Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="0.6"/>
                    <measurement group_id="O2" value="6.9" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulse Wave Velocity</title>
        <description>A measure of vascular stiffness at baseline and several hours after each experimental intervention.</description>
        <time_frame>Post PWV was taken approximately 90 min after baseline</time_frame>
        <population>Patients diagnosed with COPD compared to healthy age-matched controls.</population>
        <group_list>
          <group group_id="O1">
            <title>All COPD Patients</title>
            <description>Patients with COPD
Brachial artery flow-mediated dilation, direct assessment of oxidative stress via EPR spectroscopy (O2-) and biomarkers of oxidative stress (8-isoprostane, LH, SOD) will be assessed at baseline and 2 hours following ingestion of a single oral antioxidant cocktail (1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid.) Antioxidant Cocktail: 1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid</description>
          </group>
          <group group_id="O2">
            <title>All Controls</title>
            <description>Healthy age- and sex- matched controls
Brachial artery flow-mediated dilation, direct assessment of oxidative stress via EPR spectroscopy (O2-) and biomarkers of oxidative stress (8-isoprostane, LH, SOD) will be assessed at baseline and 2 hours following ingestion of a single oral antioxidant cocktail (1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid.) Antioxidant Cocktail: 1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid</description>
          </group>
        </group_list>
        <measure>
          <title>Pulse Wave Velocity</title>
          <description>A measure of vascular stiffness at baseline and several hours after each experimental intervention.</description>
          <population>Patients diagnosed with COPD compared to healthy age-matched controls.</population>
          <units>m/sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" spread="1"/>
                    <measurement group_id="O2" value="11" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AOC Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" spread="1"/>
                    <measurement group_id="O2" value="10" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>COPD Patients</title>
          <description>Patients with COPD
Brachial artery flow-mediated dilation, direct assessment of oxidative stress via EPR spectroscopy (O2-) and biomarkers of oxidative stress (8-isoprostane, LH, SOD) will be assessed at baseline and 2 hours following ingestion of a single oral antioxidant cocktail (1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid.) Antioxidant Cocktail: 1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid</description>
        </group>
        <group group_id="E2">
          <title>Controls</title>
          <description>Healthy age- and sex- matched controls
Brachial artery flow-mediated dilation, direct assessment of oxidative stress via EPR spectroscopy (O2-) and biomarkers of oxidative stress (8-isoprostane, LH, SOD) will be assessed at baseline and 2 hours following ingestion of a single oral antioxidant cocktail (1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid.) Antioxidant Cocktail: 1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ryan Harris, Ph.D.</name_or_title>
      <organization>Augusta University</organization>
      <phone>706-721-5998</phone>
      <email>ryharris@augusta.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

